Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal

MedGenMed Medscape General Medicine

Volumn 9, Issue 4, 2007, Pages

  Canestri, Anna ^a   Sow, Papa Salif ^b   Vray, Muriel ^c   Ngom, Fatou ^b   M'boup, Souleymane ^d   Kane, Coumba Toure ^d   Delaporte, Eric ^e   Gueye, Mandoumé ^f   Peytavin, Gilles ^a   Girard, Pierre Marie ^a   Landman, Roland ^a  

^a BICHAT HOSPITAL   (France)

^b Fann University Teaching Hospital   (Senegal)

^c INSTITUT PASTEUR   (France)

^d Laboratory of Bacteriology and Virology   (Senegal)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f HÔPITAL PRINCIPAL DE DAKAR   (Senegal)

Author keywords

Antiretroviral therapy; ART naive patient; d4T; ddI; Efavirenz; HAART; HIV; Initial ART; Senegal

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; ISONIAZID; LAMIVUDINE; RIFAMPICIN; STAVUDINE; VIRUS RNA; ZIDOVUDINE; BENZOXAZINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MEAN CORPUSCULAR VOLUME; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; SENEGAL; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ARTICLE; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM TOLERATED DOSE; METHODOLOGY; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; SURVIVAL RATE;

ADMINISTRATION, ORAL; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DEVELOPING COUNTRIES; DIDANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PATIENT COMPLIANCE; RISK ASSESSMENT; RNA, VIRAL; SENEGAL; SEVERITY OF ILLNESS INDEX; STAVUDINE; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 35248832544     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Laurent C, Diakathe N, Ngome-Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370.
2. Calmy A, Clement E, Teck R, et al. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. AIDS. 2004;18:2353-2360.
3. Dabis F, Schecter M, Egger M, et al. Response to highly active retroviral therapy in low- and high-income countries: analysis of clinical databases. Program and abstracts of the 12th-Conference on Retroviruses and Opportunistics Infections; February 22-25, 2005; Boston, Massachusetts.
4. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS. 2006;20:1497-502.
5. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. 2003;17:1017-1022.
6. Van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-999.
7. Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS. 2000;14:2485-2494.
8. Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000;14:1601-1610.
9. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS. 2003;17:2045-2052.
10. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet: 2002;360:34-40.
11. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach, 2006 revision. Available at: http://www.who.int/hiv. Accessed September 10, 2007.
12. Mutuluuza CK, Walker S, Kaleebu P, et al; for the DART trial. Short-term virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Massachusetts.
13. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8:339-346.
14. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599-602.
15. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20:1163-1169.